Merck Heart, Kidney Drug Fails Late-Stage Clinical Trial
By wchung | 07 May, 2025
Merck and Co. said Friday its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo.
The company said rolofylline did not reach its primary or secondary goals in the late-stage trial. Based on the results, Merck said it no longer plans to ask the Food and Drug Administration to approve the drug candidate this year.
The trial also showed that 30 mg of rolofylline did not reduce the risk of death or hospitalization due to heart or kidney problems 60 days after treatment, and that it did not reduce kidney impairment.
Merck is still analyzing study data from the study, which is called PROTECT, and it will present full results from the 2,033-patient trial at a medical conference later this year.
In morning trading, Merck shares fell 64 cents, or 2.4 percent, to $25.94.
6/5/2009 10:04 AM WHITEHOUSE STATION, N.J. (AP)
Articles
- Microsoft's Pavan Davuluri Unveils Low-Cost Laptop in Race for AI Users
- Anirudh Devgan Unveils AI Engineering Design Supercomputer Using Nvidia Chips
- Lisa Lu, 98, honored with Hollywood Walk of Fame Star
- Russian Beauty Captivates Chinese Social Media with Marriage Vlogs
- South Korea's Hanwha Ocean May Help Rebuild US Shipbuilding
Asian American Success Stories
- The 130 Most Inspiring Asian Americans of All Time
- 12 Most Brilliant Asian Americans
- Greatest Asian American War Heroes
- Asian American Digital Pioneers
- New Asian American Imagemakers
- Asian American Innovators
- The 20 Most Inspiring Asian Sports Stars
- 5 Most Daring Asian Americans
- Surprising Superstars
- TV’s Hottest Asians
- 100 Greatest Asian American Entrepreneurs
- Asian American Wonder Women
- Greatest Asian American Rags-to-Riches Stories
- Notable Asian American Professionals